Literature DB >> 23237908

Gene-expression profiling to identify genes related to spontaneous tumor regression in a canine cancer model.

Hsin-Chien Chiang1, Albert Tai-Ching Liao, Tong-Rong Jan, Yu-Shan Wang, Han-Jung Lei, Mong-Hsun Tsai, Mo-Fen Chen, Chien-Yueh Lee, Yi-Chen Lin, Rea-Min Chu, Chen-Si Lin.   

Abstract

Microarray transcriptome study in cancer has been commonly used to investigate tumorigenic mechanisms. The unique growth pattern of spontaneous regression (SR) after progressive (P) growth in canine transmissible venereal tumor (CTVT) provides a valuable cancer model to study the genome-wide differences in samples between the two stages of growth. In this study, Affymetrix analysis was performed based on the canine genome to compare the gene expression profiles of CTVT P- and SR-phase tumors. A total of 459 (278 up-regulated and 181 down-regulated) genes were identified as being differentially-expressed during the SR phase by the 2-fold method. Further analysis of these genes revealed that the expression of three genes associated with IL-6 production -TIMD-4, GPNMB and PLTP - was significantly higher in SR-phase tumors than in P-phase tumors; these results were also confirmed by real time RT-PCR in tumor tissues of beagles. In addition, we found that Th17-related genes were over-expressed in the SR phase, suggesting autoimmune responses involvement in tumor regression. Although the interaction between CTVT and host immunity were partially investigated in previous studies, our results enable us to gain new insight into the genes and possible mechanisms involved in tumor regression and reveal potentially useful targets for cancer therapy.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23237908     DOI: 10.1016/j.vetimm.2012.11.009

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  7 in total

1.  Activating natural killer (NK) cytotoxicity of canine CD5-CD21- cells requires low surface CD5 density NK cells.

Authors:  C S Lin; C P Chang; H C Chiang; T F Chuang; C H Hsu; C C Liu
Journal:  Iran J Vet Res       Date:  2018       Impact factor: 1.376

2.  Immunology of naturally transmissible tumours.

Authors:  Hannah V Siddle; Jim Kaufman
Journal:  Immunology       Date:  2015-01       Impact factor: 7.397

Review 3.  Necrosis, and then stress induced necrosis-like cell death, but not apoptosis, should be the preferred cell death mode for chemotherapy: clearance of a few misconceptions.

Authors:  Ju Zhang; Xiaomin Lou; Longyu Jin; Rongjia Zhou; Siqi Liu; Ningzhi Xu; D Joshua Liao
Journal:  Oncoscience       Date:  2014-07-03

4.  Genome-wide analysis of canine oral malignant melanoma metastasis-associated gene expression.

Authors:  K L Bowlt Blacklock; Z Birand; L E Selmic; P Nelissen; S Murphy; L Blackwood; J Bass; J McKay; R Fox; S Beaver; M Starkey
Journal:  Sci Rep       Date:  2019-04-24       Impact factor: 4.379

5.  Overexpression of Kynurenine 3-Monooxygenase Correlates with Cancer Malignancy and Predicts Poor Prognosis in Canine Mammary Gland Tumors.

Authors:  Yi-Han Chiu; Han-Jung Lei; Kuo-Chin Huang; Yi-Lin Chiang; Chen-Si Lin
Journal:  J Oncol       Date:  2019-05-02       Impact factor: 4.375

6.  Canine transmissible venereal tumour established in immunodeficient mice reprograms the gene expression profiles associated with a favourable tumour microenvironment to enable cancer malignancy.

Authors:  Chiao-Hsu Ke; Hirotaka Tomiyasu; Yu-Ling Lin; Wei-Hsiang Huang; Hsiao-Hsuan Huang; Hsin-Chien Chiang; Chen-Si Lin
Journal:  BMC Vet Res       Date:  2022-01-03       Impact factor: 2.741

7.  Molecular Signatures of Regression of the Canine Transmissible Venereal Tumor.

Authors:  Dan Frampton; Hagen Schwenzer; Gabriele Marino; Lee M Butcher; Gabriele Pollara; Janos Kriston-Vizi; Cristina Venturini; Rachel Austin; Karina Ferreira de Castro; Robin Ketteler; Benjamin Chain; Richard A Goldstein; Robin A Weiss; Stephan Beck; Ariberto Fassati
Journal:  Cancer Cell       Date:  2018-04-09       Impact factor: 31.743

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.